Develops therapies for rare diseases and oncology, focusing on orphan drugs and novel treatments.
Mereo BioPharma Group plc is a dynamic biopharmaceutical company dedicated to advancing therapeutics for oncology and rare diseases both domestically and globally. Founded in 2015 and headquartered in London, United Kingdom, Mereo specializes in the development and commercialization of innovative treatments. At the forefront of its pipeline is etigilimab (OMP-313M32), an antibody targeting T-cell immunoreceptors, currently undergoing Phase 1b clinical trials for tumor treatment. Additionally, Mereo is advancing Navicixizumab (OMP-305B83) for late-stage ovarian cancer, Acumapimod (BCT-197) for acute exacerbations of chronic obstructive pulmonary disease in Phase II trials, and Leflutrozole (BGS-649) for hypogonadotropic hypogonadism.
Beyond oncology, Mereo BioPharma is committed to developing therapies for rare diseases. Notable candidates include Setrusumab (BPS-804), a novel antibody designed for osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule currently in Phase II trials for Alpha-1 antitrypsin deficiency. The company collaborates with The University of Texas MD Anderson Cancer Center to advance etigilimab, reflecting its strategic partnerships and commitment to pioneering research and development in biopharmaceuticals.
Driven by innovation and guided by a robust clinical development strategy, Mereo BioPharma Group plc continues to expand its global footprint in healthcare. With a diverse pipeline addressing critical unmet medical needs, Mereo remains steadfast in its mission to improve patient outcomes through cutting-edge therapeutic solutions.